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Abstract 
 
With the spread of the AIDS pandemic, opportunistic fungal pathogens like Cryptococcus 
neoformans are a growing cause of morbidity and mortality among immunocompromised 
populations worldwide. In part owing to a common eukaryotic ancestry that results in 
shared physiology between fungal and human cells, these fungal infections are difficult to 
treat. The limited antifungal agents currently available therefore tend to target the few key 
differences between the two systems to avoid inadvertently harming the host. To address 
the current paucity of antifungal therapeutic agents, further research into fungal-specific 
drug targets is required. Adenylosuccinate synthetase (AdSS) is a crucial enzyme in the 
ATP biosynthetic pathway, catalyzing the magnesium- and GTP-dependant formation of 
adenylosuccinate from inosine monophosphate and aspartate.  
 
Over the course of my project I have investigated the potential of this enzyme as an 
antifungal drug target. By deleting the AdSS-encoding ADE12 gene from the C. 
neoformans genome, I found that loss of AdSS function results in adenine auxotrophy in 
C. neoformans, as well as complete loss of virulence in a murine infection model. In 
contrast, deleting the APH1 gene, encoding the adenine salvage enzyme adenine 
phosphoribosyltransferase, had no deleterious effects on cell growth or virulence in the 
murine model. I expressed and purified Cryptococcal AdSS from Escherichia coli and 
optimised conditions to generate high-quality AdSS protein crystals. These were used to 
complete X-ray diffractions studies, allowing me to determine the crystal structure of the 
enzyme. The structure of the enzyme’s unbound form was solved first, and then used to 
solve the structure of the enzyme ligated with IMP and GDP. These are the first examples 
of an AdSS crystal structure from a fungal species. Together with enzyme kinetic studies, 
this structural information allowed me to compare the fungal enzyme with the human 
ortholog. This revealed species-specific differences that are potentially exploitable via 
rational drug design. These results validate AdSS as a promising antifungal drug target 
and lay a foundation for future in silico and in vitro screens for novel antifungal 
compounds. 
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Chapter 1: Literature review 
The past 30 years have seen the rate of immunodeficiency skyrocket. The HIV/AIDS 
pandemic afflicts an estimated population of 34 million (1). Organ transplants are now a 
common surgical procedure, one that requires regimens of immunosuppressive drugs to 
combat rejection (2). Severe burn victims undergoing heavy steroid treatment (3), sufferers 
of autoimmune disorders taking immunosuppressants (4), patients with congenital 
immunodeficiencies (5) or type-1 diabetes mellitus (6), cancer patients undergoing 
chemotherapy (7) – while improvements are made on these fronts every year, the portion of 
our population living with reduced or diminished immunity is still very high. These 
populations are vulnerable to infection by opportunistic pathogens - pathogens that are 
easily repelled by healthy individuals, but have devastating affects in those with 
compromised immune systems.  
Fungal infections embody this idea of opportunistic pathogenesis. The number of serious 
pathogenic fungal species is relatively low, compared to the myriad diseases caused by 
bacteria or viruses, and those that are pathogenic are often more inconvenient rather than 
life threatening such as athlete’s foot or thrush. On the other hand, some of the worst 
opportunistic infections are fungal. These opportunistic pathogens share several common 
traits that set them apart from other species. They often live in ecological niches that 
ensure patient exposure occurs on a near constant basis: some are ubiquitous in the 
natural environment with infectious units abundant in the air or soil, while others live as 
part of the microbial flora of our own bodies. They also often possess phenotypes evolved 
and conserved in response to their environmental niche that become virulence factors 
when they enter a host environment.  
Three such species are recognized as the most common opportunistic fungal pathogens of 
the immunocompromised: the commensal yeast Candida albicans; the environmental 
filamentous fungi Aspergillus fumigatus; and the basidomycete yeast Cryptococcus 
neoformans, one of the primary AIDS-defining infections.  
C. neoformans has a ubiquitous environmental presence, and is most abundant in soil 
contaminated by bird droppings. On a global scale, the most recent data from the Centers 
for Disease Control and Prevention estimate an affected population of up to 1.5 million 
people each year, with the majority of cases (up to ~1 million) occurring in sub-Saharan 
Africa (8). Infection occurs via the lungs by inhalation of spores or desiccated yeast cells (9). 
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It is able to grow at human body temperature (10), and produces a polysaccharide capsule 
that protects it from opsonisation and attack by macrophages (11, 12). It also produces the 
pigment melanin, which in its natural habitat may protect it from UV radiation (13). In the 
human body, the pigment instead protects C. neoformans from the toxic free radicals 
deployed by the immune system (14, 15). Even when infecting healthy patients it can lie 
dormant in the lungs in granulomas, re-emerging to cause serious disease if its host’s 
immunity is compromised. In the worst infections, the fungus disseminates from the lungs 
and into the central nervous system to cause cryptococcal meningoencaphalitis, which is 
invariably fatal if left untreated. 
One of the biggest difficulties in treating C. neoformans, and fungal infection in general, 
lies in the similarity of their physiology to that of human cells, which is based on their 
common eukaryotic ancestry. Antifungal agents tend to target the few key differences 
between the two systems to avoid indiscriminately damaging both host and pathogen.  
One of the main differences between fungal and animal cells is the presence of ergosterol 
in fungal cell membranes, which is structurally distinct from cholesterol in animal cells. The 
azole class of antifungals target the biosynthesis of this molecule, specifically the enzyme 
lanosterol 14 α-demethylase. This enzyme catalyses the oxidation of the 14α-methyl 
group of the precursor molecule lanesterol, and the disruption of this action adversely 
affects the integrity and permeability of the fungal cell membrane (16-18). Fluconazole was 
one of the earliest and more widely used azole compounds, and the class has been 
refined since its introduction 1980s, with alterations to the base triazole structure 
conferring increased fungistatic activity to a broader range of species. However, toxicity 
and bioavailability problems limit many azoles to topical use, they are fungistatic rather 
than fungicidal, and few new compounds are undergoing active development (19) 
Another drug class that targets ergosterol are the polyenes, the most widely known of 
which is amphotericin B. Developed in the 1950s, polyenes achieve their fungicidal effect 
by binding directly to ergesterol in the fungal membrane, disrupting the integrity of the 
membrane by forming pore-like structures that allow the contents of the fungal cell to 
escape (16, 20). Polyenes preferentially bind to ergosterol, which is what grants amphotericin 
B its broad-spectrum fungal-specific activity (21). However, the selectivity of this compound 
for ergosterol over other sterols is weak – it is still able to form pores in lipid membranes 
by binding to other sterols, or without binding to anything at all (22). This results in toxicity to 
animal cells, with side effects including liver and renal damage (16, 23). Despite these 
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shortcomings, our mainstay antifungal treatment regimen currently relies on the polyene 
amphotericin B, along with the azole fluconazole, and work is ongoing to develop lipid 
formulations of amohotercin B that reduce its harmful side effects (24).  
Not all antifungals target molecules that are uniquely fungal; a notable exception are the 
sordarin class. A natural product from the fungus Sordaria araneosa, sordarin was first 
discovered in 1971 (25). Interest in the compound waned in the early 70s, but was rekindled 
when it performed well in a screen for protein synthesis inhibitors in C. albicans (26). Unlike 
other antifungals that target the cell wall or membrane, sordarins inhibit fungal protein 
synthesis by stabilizing the complex between elongation factor 2 and the ribosome, 
arresting the translocation of the ribosome along mRNA. While this target exists in humans 
as well, sordarins only recognise the fungal elongation factor (27). With their specificity, 
ease of synthesis and unique mode of action, Sordarins make for a very promising 
prospect for future antifungal drugs. Unfortunately, few have entered clinical development 
and many have had their studies discontinued (19, 26). 
The discovery and development of new fungal-specific compounds is a high priority, and 
the selectivity exhibited by the sordarin drug class suggests that more fungal-specific drug 
targets exist outside of the traditional gross differences. One approach to repopulating the 
antifungal pipeline may be to apply drug design techniques towards targeting fungal-
specific aspects of otherwise conserved metabolic enzymes. 
The purine metabolic pathway (Fig 1) is the archetypal system in which Gertrude Elion 
pioneered the concept of rational drug design (28) which involves the use of metabolic, 
genetic and structural studies to identify potential targets, followed by the directed search 
for compounds that specifically inhibit the process in question. In this way, purine 
biosynthesis has served as a source of targets for therapeutic compounds for over half a 
century, and several drugs used today target this system; for example, the 
immunosuppressive agent mycophenolic acid (29) and the anticancer compound 6-
mercaptopurine (30). 
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Fig 1: Canonical de novo purine biosynthetic pathway (31). Reaction products are indicated 
in black, while responsible enzymes are indicated in blue. Greyed-out reaction steps are 
present in other organisms, but absent in C. neoformans. 
Purine metabolism is of particular importance in C. neoformans because of the disparity 
between the pathogen’s natural niche and the human body. In nature, C. neoformans is 
most abundant in bird guano, which is extremely purine-rich. In comparison, the human 
body, especially the central nervous system, is purine-poor (32). During infection, C. 
neoformans must therefore synthesise the purine nucleotides it requires de novo, 
rendering the fungus vulnerable to inhibition of its purine biosynthetic systems (31). 
Previous studies by our group have begun to probe this vulnerability by characterising C. 
neoformans GTP biosynthetic enzyme IMP dehydrogenase (31, 33). These studies laid a 
foundation for the search for new inhibitors of this enzyme and illuminated the potential of 
de novo purine biosynthesis as a source of antifungal targets. Here we have evaluated the 
other branch of the purine biosynthesis pathway, ATP biosynthesis. Adenylosuccinate 
synthetase (AdSS) catalyzes the first committed step in the biosynthesis of ATP, the 
formation of adenylosuccinate (s-AMP) from inosine monophosphate (IMP) and aspartate. 
AdSS is an essential enzyme for most organisms and cell types studied thus far, with the 
exception of mature human erythrocytes (34) and certain obligate parasites (35).  
While bacteria and most eukaryotes have only one form of AdSS, in vertebrates the 
enzyme exists as both a basic/muscle form and an acidic/non-muscle form, each encoded 
by different genes. These isoforms are believed to play slightly differing roles in purine 
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metabolism – the acidic form is involved in de novo purine biosynthesis, while the basic 
form helps regulate ATP/GTP homeostasis (36-38). 
The AdSS mediated production of s-AMP is GTP- and Mg2+-dependent and proceeds via 
two steps. First, the γ-phosphate from GTP is transferred to the 6-oxygen of IMP, forming 
the intermediate 6-phosphoryl IMP (6-PIMP). The 6-phosphoryl group is then displaced by 
the α-amino group of aspartate to form adenylosuccinate (39). 
The first reported crystal structure of an AdSS enzyme was from Escherichia coli, and it 
remains the best characterised form of this enzyme (Fig 2) (40, 41). E. coli AdSS is a 
functional homodimer, with its structure comprised of a nine-stranded β-sheet backbone 
and four large subdomains. Directed mutagenesis studies have identified a deep crevice 
between these domains as the enzyme’s active site (42, 43) and it is only when the enzyme 
binds IMP that this active site becomes fully ordered (44). Without ligands, AdSS is believed 
to exist in an equilibrium between dimeric and monomeric states (45). IMP binding stabilises 
the coupling of the monomers into a functional homodimer, shifting the equilibrium in 
favour of the dimer (45, 46). While both AdSS subunits contain a separate active site, a 
conserved arginine side-chain from each subunit projects across the dimeric interface and 
contributes to the active site of the other subunit. AdSS must therefore be in its dimeric 
conformation to possess a complete active site, as this arginine assists the binding of IMP 
and GTP (40, 47).  Subsequent studies showed that the structure and mechanism of E. coli 
AdSS is conserved in other species including Plasmodium falciparum (48), Arabidopsis 
thaliana (49) and mice (50). Prior to this work, no structure of AdSS from a fungal species 
had been reported. 
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Fig 2: Crystal structure of AdSS from E. coli, representing the general model of AdSS 
structure. (A) Crystal structure of E. coli AdSS monomer (shown in cartoon form) bound to 
IMP and GDP and rotated clockwise in 90º increments. Bound ligands IMP and GDP are 
shown in stick form, colored orange. (B) Surface mesh of E. coli AdSS monomer, 
displaying active site face. Flexible loops are shown in closed position over the active-site 
cleft. IMP is visible in stick form, colored orange. The PDB ID for the E. coli structure is 
2GCQ. 
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There are three well-characterised inhibitors of AdSS, each of which targets a different 
aspect of this enzymatic reaction: alanosine, hadacidin, and hydantocidin (Fig 3). None of 
these inhibitors have so far been shown to have any antifungal activity. 
 
Fig 3: Structures of inhibitors of AdSS. 
Alanosine is a compound produced by Streptomyces alanosinicus, found to have 
antibiotic, antitumor, antiviral and immunosuppressive activities (51). The compound inhibits 
AdSS’s activity (52) but has no significant activity against AdSS on its own (53). Instead, 
alanosine is conjugated with 5-amino-4-imidazolecarboxylic acid ribonucleotide (AICOR) 
by AICAR synthetase, an enzyme involved in de novo IMP synthesis. The resulting 
molecule L-ananosyl-AICOR is competitive with IMP (54). Phase II clinical trials have been 
performed testing alanosine’s effectiveness against Methylthioadenosine phosphorylase 
(MTAP)-deficient tumours, which are reliant on de novo purine biosynthesis (55). 
Unfortunately, the drug was found to be ineffective and has not seen further clinical 
development. 
Hadacidin is an antitumor and anti-microbial compound first isolated in 1962 from the broth 
of Penicillium frequentans (56). Initially named after its ability to inhibit the growth of human 
adenocarcinoma cells, Hadacidin also has inhibitory activity against plants (57) and bacteria 
(58). It is a catalytically inactive analogue of L-aspartate, the addition of which has been 
found to competitively inhibit the compound’s activity (59). Hadacidin appears to possess no 
other biological function besides the inhibition of AdSS (60). Analogues of hadacdin have 
also been tested for activity against AdSS (61), but the compound has not been developed 
further since.  
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Finally, Hydantocidin is produced by Streptomyces hygroscopicus, and was first 
discovered in 1990. It is an herbicide with a broad range of activity against plants, but no 
toxicity against microbial or animal organisms (62). The compound was found to be a pro-
drug that binds to AdSS after being phosphorylated to hydantocidin 5'-monophosphate. 
Activated hydantocidin achieves its inhibitory effect by mimicking AMP (63). Physically 
linking hydantocidin and hadacidin together creates a bi-substrate hybrid inhibitor with 
potent activity against AdSS in vitro (64), but the compound has not seen further 
development and hydantocidin does not see commercial use. 
During my project, I have investigated the potential of AdSS as a candidate antifungal drug 
target in the fungal pathogen C. neoformans. I have assessed the impact of loss of AdSS 
function on C. neoformans growth, virulence factor production and virulence in an animal 
model, characterised the kinetic properties of the cryptococcal enzyme and determined the 
C. neoformans AdSS crystal structure. Collectively, my work validates AdSS as a 
promising antifungal drug target and provides a platform for future drug design studies. 
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Chapter 2: Materials and methods  
Bioinformatic analysis 
The C. neoformans var. grubii genome sequence was reported by Janbon et al. (65). AdSS- 
and Aph1-encoding genes were identified in the C. neoformans genome by reciprocal 
best-hit BLAST analysis against the genome of Saccharomyces cerevisiae. 
Strains and media 
C. neoformans H99 is the type-strain used in C. neoformans research worldwide(65). H99 
was cultured on YPD (2% bacto-peptone, 2% agar, 1% yeast extract, 2% glucose) or YNB 
(Becton Dickinson, USA) supplemented with 2% glucose and 100 mM ammonium sulfate 
at 30 ˚C. AdSS deletion mutants are adenine auxotrophs and, as such, were grown on 
minimal YNB media supplemented with 2% glucose, 100 mM ammonium sulfate and 2 
mM adenine for all manipulations, unless otherwise stated. Cloning and plasmid 
preparation was performed in E. coli strain Mach1 (Life Technologies, USA). Genomic 
DNA for E. coli gene isolation was prepared from strain K12. Recombinant C. neoformans 
AdSS was heterologously expressed in E. coli strain BL21(DE3) (Novagen, Germany). 
Nourseothricin (clonNAT) was purchased from Werner BioAgents (Jena Bioscience, 
Germany), and G418 was purchased from Sigma, USA.  
Cloning and chimera construction 
All primers used in the study are listed in Table S1. The ADE12 deletion construct was 
created by using overlap PCR to join the following fragments: The ADE12 5′ region 
(primers UQ1742 and UQ1743, H99 genomic DNA template); the G418 resistance marker 
NEO (UQ1830 and UQ1831, plasmid pJAF1 template (66)); and the ADE12 3′ region 
(UQ1744 and UQ1745, H99 genomic DNA template). The APH1 deletion construct was 
created by using overlap PCR to join the following fragments: The APH1 5′ region (primers 
UQ1750 and UQ1751, H99 genomic DNA template); the G418 resistance marker NEO 
(UQ1834 and UQ1835, plasmid pJAF1 template); and the APH1 3′ region (UQ1752 and 
UQ1753, H99 genomic DNA template). Sequencing of plasmid constructs was performed 
at the Australian Genome Research Facility (Brisbane, Australia) and sequence traces 
were analyzed using Sequencher 4.7 (Gene Codes, USA). This construct was provided by 
Andre Koh. 
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To create complementation constructs, ADE12 from C. neoformans strain H99 was TOPO-
cloned as a PCR fragment (primers UQ1742 and UQ1745) into pCR2.1 TOPO (Life 
Technologies), then subcloned as a restriction fragment (EcoRV and Apa1) into the 
nourseothricin acetyltransferase (NAT) vector pCH233 to give the plasmid pAK07 (67). This 
construct was provided by Andre Koh. APH1 from C. neoformans strain H99 was TOPO-
cloned as a PCR fragment (primers UQ1750 and UQ1753) into pCR2.1 TOPO, then 
subcloned as a restriction fragment (SacI and Nhel) into the nourseothricin 
acetyltransferase (NAT) vector pSDMA25 to give the plasmid pKLB01 (68). This construct 
was provided by Kirsten Blake. All wild-type strains utilized and mutant strains created are 
listed in Table S2. 
To create a construct for expression of C. neoformans AdSS in E. coli, total RNA was 
isolated from C. neoformans var. grubii strain H99 using TRIzol (Invitrogen). Intron-free 
cDNA was then synthesized using a Bioline cDNA synthesis kit (Bioline). ADE12 was 
PCR-amplified, with unique restriction sites (BamHI and PstI) introduced via the 
specifically designed primers UQ2259 and UQ2260. The PCR product was then cloned 
into the TOPO pCR2.1 vector (Invitrogen), sequenced and ligated into BamHI/PstI-cut 
pQE-30 expression vector (Qiagen), which introduced an N-terminal 6×His tag 
(MRGSHHHHHHGS). This construct was provided by Dr. Carl Morrow. 
Molecular techniques 
Standard molecular techniques were performed as described by Sambrook et al. (69). C. 
neoformans genomic DNA for Southern blot analysis was prepared as described (70). 
Overlap PCR, gene deletion transformation and mutant complementation was performed 
as described (71-74) via particle delivery using a BioRad He-1000 Biolistic Device (Bio-Rad, 
USA). For Southern hybridizations, DNA was digested with the indicated enzymes, 
electrophoresed on 1% TAE- agarose gels and blotted onto Hybond-XL membrane (GE 
Healthcare, UK) using standard procedures. Probes were generated using the DECAprime 
2 Random Primed DNA Labeling Kit (Thermo Fisher, US) with PCR products amplified 
from H99 template DNA radiolabelled with α32P dCTP (PerkinElmer, USA). Blots were 
hybridized overnight at 65 ºC and membranes were exposed onto Fuji Super RX medical 
X-ray film (Fujifilm, Japan). Oligonucleotides used are detailed in Table S1. 
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Virulence factor assays 
Melanization assays were performed at 30 ˚C and 37 ˚C on solid l-DOPA media 
supplemented with 10 mM asparagine (75). Phospholipase B assays were performed on 
solid Sabouraud dextrose agar with 8% egg yolk at 30 ˚C and 37 ˚C (76). Capsule growth 
was induced by overnight growth in RPMI 1640 media plus 2% glucose and 10% fetal 
bovine serum, and stained with India-ink (Becton Dickinson) to visualize the capsule. 
Capsule sizes were determined from phase contrast images, as described previously (31). 
All media was supplemented with 5 mM adenine to enable growth of auxotrophic strains. 
Minimum inhibitory concentration assays 
MIC susceptibility testing for hadacidin was performed using the broth microdilution 
method according to CLSI (CLSI M27-A2) modified for Cryptococcus neoformans (77). The 
fungal species panel included C. neoformans H99, C. neoformans ATCC-90113, C. 
albicans ATCC-90028, Candida parapsilopsis ATCC-22019, Candida galbrata ATCC-
90030, and Aspergillus fumigatus MYA-3626. The fungal panel was tested in a 96-well 
plate format in triplicate. Approximately 170 fungal cells in liquid YNB (yeast species) 
supplemented with 2% glucose and 100 mM ammonium sulfate or RPMI 1640 (A. 
fumigatus) media supplemented with 100 mM ammonium sulfate were grown with either 
hadacidin or positive controls amphotericin B and fluconazole in a 2-fold, 12-step serial 
dilution across the long axis of the plate, starting at 0.1 mg/mL. Plates were inspected for 
cell growth at 24, 48 and 72 hours post-inoculation, and a Molecular Devices SpectraMax 
250 plate-reader was used to measure the OD600 of each well at 72h. 
Murine virulence assays and organ burden analysis 
Assessment of cryptococcal virulence in the murine model system was performed as 
described previously (78, 79). For each strain, ten 6-week old female BALB/c mice were 
infected via nasal inhalation with a 50 µL drop of PBS containing 5 × 105 fungal cells. Mice 
were weighed daily and euthanized by CO2 inhalation once body weight had dropped 
below 80% of their starting weight, symptoms of infection were judged to be severe, or on 
the final day of the experiment. For organ burden analysis, brain, lungs, liver, spleen and 
kidneys were harvested from euthanized mice. Organs were weighed, homogenized and 
plated in serial dilution on YPD media to determine colony-forming units per gram of 
organ. Organ burden data was analyzed by 1-way ANOVA with Sidak’s multiple 
comparison post-test using GraphPad Prism 6.0. 
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Ethics Statement 
This study was carried out in strict accordance with the recommendations in the Australian 
Code of Practice for the Care and Use of Animals for Scientific Purposes by the National 
Health and Medical Research Council. The protocol was approved by the Molecular 
Biosciences Animal Ethics Committee (AEC) of The University of Queensland (AEC 
approval no. SCMB/439/13/UQ/NHMRC). Infection was performed under methoxyflurane 
anesthesia, and all efforts were made to minimize suffering through adherence to the 
Guidelines to Promote the Wellbeing of Animals Used for Scientific Purposes as put 
forward by the National Health and Medical Research Council (Australia). 
Expression and purification of C. neoformans AdSS 
Early failed cloning efforts strongly suggested that the ADE12 pQE30 construct was toxic 
in E. coli. The ligation was therefore transformed into competent BL21(DE3)pLysS E. coli 
cells (Promega) expressing the pREP4 repressor plasmid to reduce “leaky” expression. 
Transformed cells were grown in terrific broth (TB) media with 100 µg/mL ampicillin, 35 
µg/mL kanamycin and 12.5 µg/mL chloramphenicol. Cultures were incubated at 37 ˚C until 
they reached an OD600 of approximately 1.0, after which they were induced with 1 mM 
IPTG and grown at 20 ˚C for 5 hours. Cell pellets were harvested and resuspended in lysis 
buffer (50 mM HEPES pH 8, 300 mM NaCl, 1 mM DTT, 30 mM imidazole, and 1 mM 
PMSF) then lysed by sonication. AdSS was purified via Ni-immobilised metal-affinity 
chromatography using HisTrap fast flow columns (GE Healthcare) and eluted over 20 
column volumes in a linear gradient of 30-500 mM imidazole. A single main elution peak 
was seen. Fractions corresponding to this peak were combined and further separated over 
a Superdex 200 size-exclusion chromatography (SEC) column (GE Healthcare) 
equilibrated in SEC buffer (10 mM HEPES ph7.5, 150 mM NaCl, 1 mM DTT) using an 
ÄKTA-Purifier FPLC system (GE Healthcare). Peak fractions were combined and 
concentrated to approximately 16 mg/mL at >99% purity estimated by Coomassie-stained 
SDS-PAGE gel and snap-frozen for storage at -80 ˚C . 
Crystallization of C. neoformans AdSS 
Purified AdSS was initially screened in its Apo form, without any additional ligands or 
cofactors. All crystallization experiments were performed using the hanging drop vapor 
diffusion method at 293 K. Initial screening for crystallization conditions was performed 
using the Index, Peg/Ion 1 and Peg/Ion 2 (Hampton Research), Pact Premier and JCSG 
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(Qiagen), Proplex and Morpheus (Molecular Dimensions), and Synergy (Jena 
Biosciences) commercial screening plates. Plates were set up by a Mosquito Nanodrop 
crystallization robot (TTP LabTech), with each drop containing 100 nL protein solution and 
100 nL reservoir solution inverted over reservoirs of 100 µL. A Rock Imager system 
(Formulatrix) was used to monitor crystal growth in the drops. Crystals were found in 
approximately 200 conditions. The most promising candidates were chosen for further 
screening and optimization. Final diffraction-quality crystals were obtained using a 
condition from the PACT screen. Drops containing 1 µL of protein solution at 16 mg/mL 
and 1 µL of reservoir solution (0.1 M BisTris propane pH 8, 0.2 M sodium bromide, 17% 
polyethylene glycol 3350) were streak-seeded from non-suitable AdSS crystals after 30 
minutes equilibration over 500 µL reservoirs. Long rectangular crystals of approximately 
0.5 × 0.05 × 0.05 mm formed after 24-48 hours. 
In addition, purified AdSS was also co-crystallized with its substrates IMP, GTP, hadacidin 
and magnesium. For co-crystallization, the protein was screened and crystallized as 
above, with the following modifications: final diffraction-quality crystals were obtained using 
a condition from the PEG/Ion 2 crystallization screen (Hampton research) in which no 
crystals were detected during screening of the apo-enzyme. Drops containing 1 µL of co-
crystallization solution (AdSS protein at 16 mg/mL in gel filtration buffer from (80), 5 mM 
IMP, 5 mM GTP, 5 mM hadacidin, 50 mM magnesium acetate) and 1 µL of reservoir 
solution (0.1 M ammonium citrate tribasic, 18% PEG3350) were equilibrated over 500 µL 
reservoirs. Long rectangular crystals formed at 18 ˚C after 24-48 hours, with no need for 
streak-seeding.  
X-ray diffraction data collection and processing 
X-ray diffraction data from AdSS crystals was collected to a resolution of 2.2 Å for the apo-
enzyme and 1.55 Å for the ligated enzyme. The data was collected on the MX2 beamline 
at the Australian Synchrotron, indexed and integrated using XDS (81) and scaled with 
AIMLESS within the CCP4 suite (82).   
The structure of apo-AdSS was solved by molecular replacement using Phaser (83) with the 
structure of the muscle isoform of mouse AdSS (PDB ID: 1J4B, 55% amino-acid sequence 
identity) as a template. Automated model building was performed using Phenix.autobuild 
(84, 85) and refinement was performed using Phenix.refine coupled with iterative manual 
adjustments using Coot (86, 87). The structure of ligated AdSS was solved by the same 
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method, using the apo-AdSS structure previously generated as the template for molecular 
replacement. Figures were generated with PyMOL (http://www.pymol.org). Data collection 
and refinement statistics for both structures are listed in Table S3. Atomic coordinates and 
structure factors of both the apo-AdSS and ligand-bound structures have been deposited 
in the Protein Data Bank, www.pdb.org (PDB IDs: 5I33 and 5I34 respectively). 
Multiangle laser light scattering with size exclusion chromatography 
Size-exclusion chromatography (SEC) – multiangle laser light scattering (MALS) was 
performed using a Dawn Heleos II 18-angle light-scattering detector coupled with an 
OptilabrEX refractive index detector (Wyatt Technology, Santa Barbara, CA, USA) and 
inline Superdex 200 10/300 size exclusion column (GE Healthcare). Experiments were 
performed at an AdSS concentration of 5 mg/mL in SEC buffer (10 mM HEPES pH 7.5, 
150 mM NaCl, 1 mM DTT) at room temperature, with a flow rate of 0.5 mL/min. 
Steady-state enzyme kinetics and inhibitor analysis 
All enzyme assays were performed as previously described (88) with some modifications. 
Enzymatic assays were performed at 25 ˚C in triplicate by monitoring the production of 
adenylosuccinate at 280 nm (ε = 11.7 mM-1 cm−1) for 5 min using a Varian Cary 60 
spectrophotometer (Agilent Technologies, USA). Assays were performed in 10 mm optical 
quartz cuvettes (Starna Scientific, UK). Each assay was performed in a total volume of 1 
mL standard AdSS assay buffer (50 mM potassium phosphate pH 7.2, 8 mM magnesium 
acetate) containing 4 µg of purified enzyme, 100 µM GTP, 150 µM IMP and 7 mM 
aspartate. For KM determination, IMP, GTP and aspartate concentrations were varied over 
ranges of: 2.5 to 200 µM for GTP; 9.5 to 300 µM for IMP; and 100 µM to 15 mM for 
aspartate. Direct nonlinear fitting of the data to the Michaelis-Menten equation was 
performed using Prism 6 (GraphPad Software, USA). 
Inhibitor IC50 values were determined by adding increasing concentrations of hadacidin (40 
to 640 µM, dissolved in water) to the aforementioned standard AdSS assay condition and 
determining the reaction velocity. Non-treated cells and solvent-only controls were also 
included. Assays were performed at 25 ˚C in triplicate by monitoring the production of 
adenylosuccinate at 280 nm (ε = 11.7 mM-1 cm−1) for 5 min using a Varian Cary 60 
spectrophotometer. Nonlinear fitting of the data to a single-phase exponential decay 
equation was performed using GraphPad Prism 6.0.
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Chapter 3: Characterization of AdSS 
Identification of the AdSS-encoding gene in C. neoformans 
In order to begin our characterization of AdSS from C. neoformans, we first identified its 
corresponding gene. As the AdSS-encoding gene from S. cerevisiae is well-characterized, 
it was used in a reciprocal best-hit BLAST analysis to identify the equivalent gene from the 
published C. neoformans genome (65). Only one hit was obtained, indicating that the gene 
is present in a single copy located on chromosome 3. This gene has the ORF designation 
CNAG_02858 and was named ADE12 after the S. cerevisiae ortholog, with which its 
predicted product is 61% identical at the amino acid level. It is 54% identical to both the 
acidic and basic isoforms of the human ortholog and 42% identical to the enzyme in E. 
coli. Areas of high conservation are found around predicted active site residues (Fig S1). 
Loss of AdSS function results in adenine auxotrophy 
To verify the function of the identified gene, we employed biolistic transformation to delete 
it from the genome of C. neoformans type strain H99. In brief, DNA constructs consisting 
of an antibiotic resistance marker flanked by the sequences immediately 5’ and 3’ of 
ADE12 in the C. neoformans genome. These constructs were then precipitated onto gold 
microbeads. Transformations were performed using a biolistic device, which uses 
compressed air to fire the DNA-coated beads into a lawn of fungal cells grown on standard 
media. Gold-impregnated cells are then scraped into solution and spread onto selective 
media. In successfully transformed cells, homologous recombination occurs between the 
fungal genome and the identical 5’ and 3’ flanking regions of the deletion construct, 
replacing the gene of interest with the payload resistance cassette. This procedure was 
carried out by Samantha Arras. 
The resulting ade12∆ strain was an adenine auxotroph, unable to grow on either rich or 
minimal media without supplemental adenine (Fig 4). Adenine prototrophy was restored 
when the deletion strain was transformed with the wild-type ADE12 gene, creating the 
complemented derivative strain ade12∆+ADE12. Auxotrophy was detected in the ade12∆ 
strain at both optimal growth temperature (30 ºC) and at human body temperature (37 ºC), 
and is consistent with previous work involving the GTP branch of the de novo purine 
synthesis pathway, where loss of IMP dehydrogenase activity resulted in guanine 
auxotrophy (31). The deletion and re-introduction of the ADE12 gene was confirmed by 
Southern blot analysis (data not shown). 
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Fig 4. The loss of AdSS activity results in adenine auxotrophy. 10-fold serial dilutions of 
the indicated strains were spotted onto either YPD complete media or YNB minimal media 
supplemented with 2% glucose and 100 mM ammonium sulfate alone, or additionally 
supplemented with 2 mM adenine. The ade12∆ deletion strain is an adenine auxotroph. 
To confirm that the protein encoded by ADE12 performed the biochemical functions of the 
AdSS enzyme, we employed a cross-species complementation approach and introduced 
purA, the AdSS-encoding gene from E. coli, into the ade12∆ mutant. The E. coli purA gene 
was transformed into the deletion strain under the control of the promoter and terminator 
regions from C. neoformans ADE12. This ade12∆+PURA strain displayed a partial 
complementation of the deletion mutant’s adenine auxotrophy (Fig 5). Taken together, 
these results confirm that the adenine auxotrophy phenotype was due to the loss of AdSS 
activity. 
 28 
 
Fig 5. Introduction of E. coli ortholog purA partially reverses the adenine auxotrophy of the 
ade12∆ mutant. 10-fold serial dilutions of the indicated strains were spotted onto YNB 
minimal media supplemented with 2% glucose and 100 mM ammonium sulfate. The 
adenine auxotrophy of the ade12∆ mutant is only partially complemented by the E. coli 
gene. 
Loss of AdSS function does not influence virulence factor production 
C. neoformans possesses several virulence factors that help it establish and maintain 
infection in a human host. Key among these are the polysaccharide capsule, which 
defends against macrophage attack and opsonization; melanin, which defends the cell 
from free radicals; urease, which assists with dissemination from the lungs; and the ability 
to grow at human body temperature. 
We investigated the effects of the deletion of the AdSS gene on C. neoformans virulence 
factor production by testing the ade12∆ strain and its complemented derivative in a variety 
of in vitro assays. In contrast to changes in virulence factor production described 
previously in the imd1∆ GTP biosynthesis mutant (31), ade12∆ displayed no defect or delay 
in any of the phenotypes tested (Fig 6). When grown on l-DOPA media, the deletion strain 
displayed melanin production comparable to that of the wild-type strain. India-ink staining 
revealed no significant reduction in the mutant’s production of the polysaccharide capsule. 
ade12∆ had no detectable effect on the fungus’ response to the cell wall stressors 
caffeine, calcofluor white and congo red, and there was also no defect in the production of 
phospholipase B in the deletion strain. Across all tests, ade12∆ displayed no defect in 
growth at 30 or 37 ˚C compared to the wild-type strain.  
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Fig 6. Loss of AdSS activity does not impact on virulence factor production. (A) The 
indicated strains were spotted onto L-DOPA melanization media or egg yolk media and 
incubated for 48 h at 30 ºC or 37 ºC. (B) The indicated strains were grown in RPMI 1640 
media plus 10% BSA and 2 mM adenine at 30 ºC or 37 ºC for 24 h.  Capsule was 
visualized by India-ink staining, and the relative capsule diameter was measured. Cell 
diameters of mutant and complement strains were compared to the wild-type strain using a 
1-way ANOVA with Sidak’s multiple comparison post test. No significant reduction of 
capsule diameter was detected at either temperature tested. A slight increase in capsule 
diameter was detected in ade12∆ at 30 ºC (P ≤ 0.0001), and in ade12∆+ADE12 at 37 ºC 
(P ≤ 0.01). 
Identification of the gene required for adenine salvage in C. neoformans 
In addition to de novo biosynthesis, C. neoformans is able to synthesize ATP by another 
route – it can take up purines from its environment via the purine salvage pathway, and it 
is through this activity that we can culture the ade12∆ mutant in the presence of adenine. 
To validate the AdSS-dependent de novo synthesis of ATP as a potential target for drug 
development, we first had to confirm that this alternative mechanism of ATP synthesis was 
not important during the infection process. Therefore, while characterizing the ATP branch 
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of the biosynthetic pathway, we also investigated the adenine salvage enzyme adenine 
phosphoribosyltransferase. The adenine phosphoribosyltransferase-encoding APH1 gene 
was identified in the C. neoformans genome using reciprocal best-hit BLAST analysis 
against the orthologous S. cerevisiae gene APT1. It has the locus number CNAG_01390, 
is located on chromosome 5 in a single copy and, like ADE12, is highly conserved; the 
predicted product has 51% and 40% identity to the S. cerevisiae isoforms 1 and 2 
respectively; 46% against the human; and 41% against the E. coli enzyme. 
Loss of adenine salvage function does not influence virulence factor production 
In order to investigate the impact of APH1 on virulence, we employed biolistic 
transformation to delete it from the type strain H99, and to complement the deletion mutant 
with the wild-type gene, creating the strains aph1∆ and aph1∆+APH1. These strains were 
created by Adre Koh and Kirsten Blake, respectively. 
As expected, aph1∆ did not display adenine auxotrophy, with both the deletion and 
complementation strain able to grow on minimal media without supplementation (Fig 4). 
The aph1∆ strain was also tested for the production of key virulence factors, but was found 
to be indistinguishable from the wild-type strain under all conditions tested (Fig 7).  
 
Fig 7: Loss of adenine salvage does not impact on virulence factor production. The 
indicated strains were spotted onto L-DOPA melanization media or egg yolk media and 
incubated for 48 h at 30 ºC. The indicated strains were also grown in RPMI 1640 media 
plus 10% BSA at 30 ºC for 24 h.  Capsule was visualized by India-ink staining, 
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Loss of adenylosuccinate synthetase activity renders C. neoformans avirulent in 
vivo 
The dramatic loss of in vivo virulence displayed by IMP dehydrogenase deletion strains (31) 
makes it clear that C. neoformans cannot cause a life-threatening infection without this 
step of de novo GTP biosynthesis. What is not clear is whether this attenuation is due to 
the mutant’s observed delay in virulence factor production, guanine auxotrophy, or a 
combination of the two. 
With AdSS we expected no such ambiguity, as virulence factor production in the ade12∆ 
mutant was not affected. We used the murine inhalation model of cryptococcosis to 
compare the virulence of the wild-type, ade12∆ and aph1∆ strains, and their 
complemented derivatives. Mice infected with the wild-type strain succumbed to infection 
within 24 days. There was no significant difference between this result and mice infected 
with the aph1∆ deletion mutant, or the aph1∆+APH1 and ade12∆+ADE12 complemented 
strains. In contrast, mice infected with the ade12∆ deletion strain remained healthy even 
up to 32 days post-infection (Fig 8A). Subsequent analysis of fungal organ burden of 
culled mice revealed that those infected with the wild-type, aph1∆ and both complemented 
strains suffered significant fungal colonization of the lungs and dissemination to all organs 
tested. Those infected with the ade12∆ strain had cleared their infection, with no fungal 
cells present in any organs tested (Fig 8B). Time-course experiments were conducted to 
determine whether this effect was truly due to loss of virulence and eliminate the possibility 
that the infection inoculum were simply not viable without adenine. We found that the 
ade12∆ deletion strain was able to survive for over 9 hours after being transferred from 
adenine-supplemented to non-supplemented media (data not shown). This is in line with 
our previous studies in guanine biosynthesis, in which it was found that IMPDH-deficient 
cells were able to infiltrate from the lungs of infected mice, only to be rapidly cleared (31). 
 
 32 
 
Fig 8. ADE12 is essential for virulence and dissemination in a mammalian host, while 
APH1 is not. (A) Survival of female BALB/c mice infected with 5 × 105 cells by nasal 
inhalation. (B) Fungal burden of organs recovered from infected mice.  
Organ burden of mutant and complement strains was compared to the wild-type strain 
using a 1-way ANOVA with Sidak’s multiple comparison post-test. In all organs tested, 
ade12∆ was found to be significantly lower (P ≤ 0.0001). No significant difference was 
found in any other strain in any organ tested. 
 33 
The fact that ade12∆, with its fully functioning suite of virulence factors, displayed the 
same loss of virulence as previously reported for IMP dehydrogenase deletion mutants 
indicates that this effect is likely mediated solely by purine auxotrophy. Additionally, the 
adenine salvage pathway was found to be expendable during infection, in line with 
previous deletion studies in guanine salvage (31), again highlighting the importance of de 
novo purine biosynthesis during the infection process; Cryptococcus causes deadly fungal 
meningoencephalitis after disseminating to the central nervous system, which is relatively 
poor in purines compared to the fungus’ native environment (32). Our data support the 
model that C. neoformans is entirely reliant on its de novo purine biosynthesis during 
infection, as there are insufficient salvageable purines in the cerebrospinal fluid to support 
growth. If deprived of de novo purine synthesis during infection, the production of virulence 
factors would be irrelevant, as the fungus would be unable to grow at all. This represents a 
fundamental and potentially crippling vulnerability within the fungus, one that should be 
exploited through rational drug design. 
Steady-state enzyme kinetics of cryptococcal AdSS 
The development of targeted antimicrobial drugs requires an established assay with which 
to assess the activity of new compounds. Furthermore, insights into the kinetic parameters 
of the target enzyme are required to characterize the mechanism of action by possible 
drug candidates. Differences in the kinetic parameters between orthologous enzymes may 
also indicate potentially exploitable mechanistic differences or structural features. In the 
case of AdSS, the conversion of IMP and l-aspartate to adenylosuccinate proceeds via two 
steps, as confirmed and exemplified by the well-studied AdSS enzyme in E. coli (89). In the 
first step, the γ-phosphate from GTP is transferred to the 6-oxygen of IMP. This forms the 
intermediate 6-phosphoryl IMP (6-PIMP) with the 6-phosphoryl group then displaced by 
the α-amino group of aspartate to form adenylosuccinate (Fig 9A). 
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Fig 9. Enzyme kinetics of C. neoformans AdSS. (A) AdSS enzyme reaction scheme. (B) 
Substrate concentration (µM) vs enzyme velocity (∆Abs/min), with non-linear fitting of 
Michaelis-Menten equation. 
In order to characterize this reaction in the C. neoformans enzyme, we created a gene 
construct that contained an N-terminal 6×His-tag fused to the C. neoformans AdSS. This 
tagged enzyme was expressed in E. coli and purified the protein by nickel affinity and size-
exclusion chromatography (80). Pure recombinant C. neoformans AdSS was used to 
determine the steady-state parameters of the enzyme (Fig 9B). The purified enzyme was 
enzymatically active, as shown by an increase in adenylosuccinate specific absorption at 
280 nm. Cryptococcal AdSS displayed a relatively high kcat of 3.21s-1, between 3- and 5-
fold higher than reported in other species (Table 1). This may explain why 
complementation with the E. coli enzyme only partially reversed the auxotrophy of the 
ade12∆ strain.  
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Table 1. Comparison of reported kinetic paramaters of AdSS from multiple species. 
Species kcat (S-1) KM IMP (µM) KM GTP (µM) KM aspartate (µM) 
C. neoformans 3.21 25.30 ± 1.8 16.3 ± 1.3 2330 ± 197 
S. cerevisiae (88) 0.2 200 ± 18 81 1650 
P. falciparum (90) N/A 22.8 4.8 1400 
E. coli (43) 0.59 21 ± 2 22 ± 5 280 ± 40 
M. musculus muscle (50) 1.0 45 ± 7 12 ± 2 140 ± 15 
H. sapiens muscle (91) 0.2 N/A N/A N/A 
 
The C. neoformans enzyme also exhibited a very high KM for aspartate (2330 ± 197 µM), a 
trait shared with enzymes from S. cerevisiae and P. falciparum, but not the bacterial or 
mammalian orthologs. The reported IMP and GTP Km values for the S. cerevisiae enzyme 
are approximately 8-fold higher than those from C. neoformans (25.3 ± 1.8 µM for IMP, 
16.3 ± 1.3 µM for GTP), which are more in line with those reported for E. coli AdSS (Table 
1). Unfortunately, little work towards characterizing human AdSS has been reported, 
making direct comparison of KM values impossible. The AdSS muscle isozyme from mice 
has been characterized, with a 55% higher KM for IMP than the C. neoformans enzyme 
and an equivalent KM for GTP.  
An existing AdSS inhibitor exhibits limited antifungal activity  
When searching for antimicrobial compounds, finding an already well-established drug that 
is active against a new organism of interest can be a significant advantage, as synthesis 
methods, commercial stocks or even clinical trial data may already be available. AdSS 
currently has a limited number of well-characterized inhibitors, including the antibiotic l-
aspartate analogue hadacidin (60). We determined whether this compound was capable of 
recreating the ade12∆ auxotrophy phenotype in a range of pathogenic fungi. 
We assayed the minimum inhibitory concentration of hadacidin in adenine-free media 
against a panel of six fungal strains: two C. neoformans isolates, as well as C. albicans, C. 
parapsilopsis, C. glabrata and A. fumigatus. Fungal cells were exposed to increasing 
concentrations of hadacidin to determine minimum inhibitory concentration for each strain. 
The concentrations tested – a 12-step, 2-fold serial dilution starting at 0.1 mg/mL (168 µM) 
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and ending at 0.5 µg/mL (4 µM) – were chosen based on previously reported in vivo 
experiments (32), as well as limited compound availability.  
We found that only one assayed combination exhibited any change in fungal growth; 168 
µM hadacidin, the highest concentration tested, lead to reduced growth of C. albicans. 
OD600 of the treated assay condition at 72h dropped to an average value of 0.877 
compared to 0.995 in the adjacent condition treated with 84 µM hadacidin and 1.085 in the 
untreated condition. No other strains, including both C. neoformans isolates, exhibited any 
inhibition of growth when exposed to the drug. 
The lack of even moderate antifungal activity of hadacidin against C. neoformans could 
easily be explained by either poor compound entry into the cell, or insensitivity of the 
enzyme to this inhibitor. To determine whether hadacidin was active against the 
cryptococal enzyme despite having no anticryptococcal activity at the concentrations 
tested, we determined the IC50 value of the compound against purified C. neoformans 
AdSS in our in vitro assay.  
50% reduction in reaction velocity was found to occur at 255 µM, a concentration that 
exceeds the highest tested in our MIC assays. Other potential factors, including 
degradation of hadacidin in the media and problems with uptake into the cytoplasm, could 
also have lowered the functional concentration in the fungal growth inhibition MIC assay 
further. Furthermore, during the IC50 determination, we found that the rate of decrease of 
AdSS velocity with respect to hadacidin concentration followed an exponential decay curve 
that plateaued at 30% remaining activity (Fig 10). This indicates that hadacidin would likely 
be unable to fully inhibit the activity of C. neoformans AdSS, even at millimolar 
concentrations. In light of these results, it is also reasonable to conclude that hadacidin is 
not an inhibitor of C. neoformans AdSS under these conditions  
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Fig 10. Hadacidin could not fully inhibit C. neoformans AdSS activity. Hadacidin 
concentration (µM) vs percent enzyme activity with non-linear fitting of single-phase 
exponential decay equation. 
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Chapter 4: AdSS crystallization 
This paper was submitted to Acta Crystallographica Section F (Structural biology and 
crystallization communications), and published in 2013. It encompasses my efforts to 
express and purify C. neoformans AdSS in E. coli, optimize conditions for crystallizing 
AdSS, and the preliminary analysis of X-ray diffraction data obtained from the resulting 
crystals. For brevity and convenience, references to figures and tables in the originally 
published paper have been altered to refer to equivalent figures and tables reported 
elsewhere in this manuscript where possible, and the original paper’s reference list has 
been incorporated into this manuscript’s reference section. 
I completed the experimental work (90%) with some preliminary preparation performed by 
Carl Morrow (5%). I performed the data analysis (70%) with assistance from Simon 
Williams (20%) and Daniel Ericsson (10%). I designed the experiments (80%) with 
assistance from Simon Williams (20%). I wrote the text of the paper (85%) with drafting 
assistance from James Fraser, Bostjan Kobe, and Simon Williams (5% each). 
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Introduction 
With the rise of the HIV/AIDS pandemic and the increased use of immunosuppressive 
drugs in chemotherapy and organ transplantation, populations of individuals with defective 
immune systems are higher than ever before. With such a large immunocompromised 
population, opportunistic infections are a growing cause of morbidity and mortality. Among 
these opportunists is the fungus Cryptococcus neoformans, one of the foremost AIDS-
defining illnesses. Infection by this basidiomycete yeast begins with inhalation of spores or 
desiccated yeast cells (92). Individuals with healthy immune systems generally clear 
infection by C. neoformans. However, in immunocompromised individuals, the fungus can 
disseminate to the central nervous system to cause cryptococcal meningoencaphalitis, 
which is fatal if untreated (92). 
Fungal infections are difficult to treat due to the similarities of their eukaryotic physiology to 
that of humans; the limited antifungal agents available tend to target the few differences 
between the two systems (16). Azoles (such as fluconazole) and polyene compounds (such 
as amphotericin B) target ergosterol by inhibiting the enzyme involved in its biosynthesis 
(lanosterol 14 α-demethylase), or by binding to ergosterol itself, respectively. New agents 
of this class are frequently reported, however few see active clinical development (19). 
Sordarins, which inhibit protein synthesis via elongation factor 2 (27) and echinocandins, 
which inhibit fungal cell wall glucan synthesis (93), both show promise as antifungal agents, 
but few specific candidates for further trials have emerged (19) Considering the current 
shortage of new drug candidates in the antifungal pipeline, the discovery and development 
of novel fungal-specific compounds needs to be given a high priority. One approach to 
achieve this is to apply rational drug design techniques towards fungal-specific aspects of 
otherwise conserved metabolic pathways.  
The purine metabolic pathway has for over half a century served as a source of targets for 
therapeutic compounds including antitumor drugs, immunosuppressants and antivirals (28). 
Previous studies by our group have shown that purine metabolism is a potential source of 
antifungal drug targets to combat C. neoformans infection (31, 33). We have already 
characterized a crucial enzyme in the purine biosynthesis pathway in this organism, 
inosine monophosphate dehydrogenase (IMPDH). IMPDH is the first committed step in de 
novo GTP biosynthesis, catalyzing the conversion of inosine monophosphate (IMP) to 
xanthosine monophosphate (XMP). Loss of IMPDH activity, and consequently de novo 
GTP biosynthesis, results in the death of the pathogen, suggesting that this pathway may 
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be a viable antifungal target (31). To further probe this pathway for targets, we have 
investigated other purine biosynthetic enzymes. 
Just as IMPDH catalyzes the first step in GTP biosynthesis from IMP, the first step in the 
conversion of IMP to ATP is governed by the enzyme adenylosuccinate synthetase 
(AdSS). AdSS catalyzes the formation of adenylosuccinate (s-AMP) from IMP and 
aspartate. This GTP and Mg2+ dependent reaction proceeds via two steps: firstly, the γ-
phosphate from GTP is transferred to 6-oxygen of IMP, forming the intermediate 6-
phosphoryl IMP (6-PIMP); secondly, the 6-phosphoryl group is displaced by the α-amino 
group of aspartate to form adenylosuccinate (39) (Fig 9A). Structural studies in Escherichia 
coli and other organisms have shown that the enzyme forms a dimer, with each subunit 
contributing an arginine residue to the active site of the other molecule (40, 41, 47, 48). In the 
absence of its substrate, the active site of AdSS is disordered, however upon ligand 
binding, the substrate binding pocket and dimer formation are stabilized (44, 94). 
With the exception of mature red blood cells, AdSS is an essential enzyme in all 
organisms studied so far and most cell types, (44, 95). An alternative route of ATP 
biosynthesis is the conversion of adenine salvaged from the environment to adenosine 
monophosphate (AMP). This reaction is governed by the enzyme adenine phosphoribosyl 
transferase (APRT), which has been characterized in several organisms including the 
fungus Saccharomyces cerevisiae (96). C. neoformans carries a predicted APRT-encoding 
gene (strain H99; CNAG_02858, Broad Institute of MIT and Harvard;  
www.broadinstitute.org/annotation/genome/cryptococcus_neoformans/MultiHome.html). 
AdSS has been purified and characterized from several sources. AdSS from E. coli is 
arguably the best characterized (41, 97, 98) and has 42% identity with the cryptococcal 
enzyme. Crystal structures are also available for the proteins from Homo sapiens (54%, 
PDB ID: 2V40); Mus musculus (54%, (50, 99)); the bacteria Yersinia pestis (42%, PDB ID: 
3HID), Campylobacter jejuni (43%, PDB ID: 3R7T) and Burkholderia thailandensis (40%, 
PDB ID: 3UE9); the plants Arabidopsis thaliana (55%) and Triticum aestivum (53%, (49)); 
the eukaryotic parasite Plasmodium falciparum (46%(48); and the extremophile archaeon 
Pyrococcus horikoshii (33%, (100)). The enzyme has been crystallized in the apo-form (41, 50) 
as well as complexed with various combinations of IMP, GTP, GDP, aspartate, 6-PIMP, 
Mg2+, and two AdSS inhibitors: the anti-tumor aspartate analogue hadacidin (56, 61) and the 
adenosine 5’-monophosphate-mimicking herbicide hydantocidin (63).  
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To date, there has been no crystallographic studies of AdSS from a fungal species. In the 
hope that comparison of a fungal AdSS structure with the comprehensive knowledge 
available from other species may prove useful in the design of future fungal-specific 
agents, here we describe the crystallization and initial analysis of the crystals of 
adenylosuccinate synthetase from C. neoformans. 
Materials and methods 
Cloning 
Total RNA was isolated from C. neoformans var. grubii strain H99 using TRIzol 
(Invitrogen). Intron-free cDNA was then synthesized using a Bioline cDNA synthesis kit 
(Bioline). The AdSS-encoding gene ADE12 (strain H99; CNAG_02858, Broad Institute of 
MIT and Harvard;  
www.broadinstitute.org/annotation/genome/cryptococcus_neoformans/MultiHome.html) 
was PCR-amplified, with unique restriction sites (BamHI and PstI) introduced via the 
specifically designed primers UQ2259 
(ACGCACGGATCCATGGCTCCATCCCCGGAGGGA) and UQ2260 
(GAACGTCTGCAGTTAGAAGATGATAACGTTCTG). The PCR product was then cloned 
into the TOPO pCR2.1 vector (Invitrogen), sequenced and ligated into BamHI/PstI-cut 
pQE-30 expression vector (Qiagen), which introduced an N-terminal 6×His tag 
(MRGSHHHHHHGS).  
Expression and purification 
Early failed cloning efforts strongly suggested that the ADE12 pQE construct was toxic in 
E. coli. The ligation was therefore transformed into competent BL21(DE3)pLysS E. coli 
cells (Promega) expressing the pREP4 repressor plasmid. Transformed cells were grown 
in terrific broth (TB) media with 100 µg/mL ampicillin, 35 µg/mL kanamycin and 12.5 µg/mL 
chloramphenicol. Cultures were incubated at 310 K until they reached an OD600 of 
approximately 1.0, after which they were induced with 1 mM IPTG and grown at 293 K for 
5 hours. Cell pellets were harvested and resuspended in lysis buffer (50 mM HEPES pH 8, 
300 mM NaCl, 1 mM DTT, 30 mM imidazole, and 1 mM PMSF) then lysed by sonication. 
AdSS was purified via Ni-immobilised metal-affinity chromatography using HisTrap fast 
flow columns (GE Healthcare) and eluted over 20 column volumes in a linear gradient of 
30-500 mM imidazole. A single main elution peak was seen. Fractions corresponding to 
this peak were combined and further separated over a Superdex 200 size-exclusion 
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chromatography (SEC) column (GE Healthcare) equilibrated in SEC buffer (10 mM 
HEPES ph7.5, 150 mM NaCl, 1 mM DTT) using an ÄKTA-Purifier FPLC system (GE 
Healthcare). Peak fractions were combined and concentrated to approximately 16 mg/mL 
at >99% purity estimated by Coomassie-stained SDS-PAGE gel and snap-frozen for 
storage at 193 K. 
Crystallization 
All crystallization experiments were performed using the hanging drop vapor diffusion 
method at 293 K. Initial screening for crystallization conditions was performed using the 
Index and Peg/Ion (Hampton Research), Pact Premier and JCSG (Qiagen), Proplex and 
Morpheus (Molecular Dimensions), and Synergy (Jena Biosciences) commercial screening 
plates. Plates were set up by a Mosquito Nanodrop crystallization robot (TTP LabTech), 
with each drop containing 100 nL protein solution and 100 nL reservoir solution inverted 
over reservoirs of 100 µL. A Rock Imager system (Formulatrix) was used to monitor crystal 
growth in the drops. Crystals were found in approximately 200 conditions. The most 
promising candidates were chosen for further screening and optimization. Final diffraction-
quality crystals were obtained using a condition from the PACT screen. Drops containing 1 
µL of protein solution at 16 mg/mL and 1 µL of reservoir solution (0.1 M BisTris propane 
pH 8, 0.2 M sodium bromide, 17% polyethylene glycol 3350) were streak-seeded from 
non-suitable AdSS crystals after 30 minutes equilibration over 500 µL reservoirs. Long 
rectangular crystals of approximately 0.5 × 0.05 × 0.05 mm formed after 24-48 hours 
(Figure 2). 
Data collection and processing 
Crystals were mounted on nylon loops and treated with a cryoprotectant before being 
flash-cooled in liquid nitrogen. Initial tests using 20% glycerol in crystallization solution 
caused crystals to shatter, so 15% ethylene glycol was used as a cryprotectant. X-ray 
diffraction was performed on the MX2 beamline at the Australian Synchrotron (Clayton, 
Australia). Reflections were indexed and integrated using the program XDS (101) then 
scaled using Aimless as implemented within the CCP4 suite (82) 
 
 
 43 
Results and discussion 
Full-length His-tagged AdSS from C. neoformans was expressed heterologously in soluble 
form in E. coli after 5 hours induction at 293 K. Protein appeared as a single band of 
approximately 46 kDa on reducing SDS-PAGE gels, matching the estimated size of His-
tagged AdSS. During SEC, the protein elutes at 220 mL, which, based on its expected 
molecular weight and protein calibration standards, suggests a monomeric state in 
solution. This is in keeping with the established model in which AdSS dimerization is 
dependent on ligand binding (46).  
Following the large number of hits obtained from initial sparse-matrix screening, trends in 
crystallization conditions were investigated. Many hits occurred in conditions using 
PEG3350 as a precipitant with various types of salts. After comparing the morphologies of 
these hits, a buffer containing PEG3350 and sodium bromide was chosen. Further rounds 
of optimization by varying pH, PEG concentration, and the addition or absence of glycerol 
led to large, diffraction quality crystals in 0.1 M BisTris propane, pH 8, 0.2 M sodium 
bromide and 17% polyethylene glycol 3350. Protein crystals appeared after 24-48 hours at 
293 K (Fig 11). The resolution of the best-diffracting crystals was 2.2 Å. Data collection 
and refinement statistics are summarized in Table S3. The crystals most likely contain 2 
molecules in the asymmetric unit (corresponding to the Matthews coefficient of 2.61 Å3/Da) 
(102). 
Current work is focusing on solving the structure of AdSS by molecular replacement based 
on the most similar crystallized homologue (A. thaliana) as well as obtaining datasets for 
ligand- and inhibitor-bound forms. Analysis of these structures may reveal differences from 
the human enzyme that could be exploited by structure-based inhibitor design to create 
leads for new antifungal therapeutics. 
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Fig 11, Crystals of adenylosuccinate synthetase from C. neoformans, space group 
P212121. 
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Chapter 5: AdSS apoenzyme. 
Crystal structure of unligated cryptococcal AdSS 
To enable comparisons between the C. neoformans enzyme and those from other 
species, and identify targetable species-specific features, we determined the crystal 
structure of the C. neoformans AdSS apo-enzyme to 2.2 Å resolution. The C. neoformans 
AdSS structure contained two molecules within the asymmetric unit, which resembled the 
functional homoodimer observed in other AdSS crystal structures (Fig 12A). The overall 
structure of the enzyme was very similar to the well-characterized E. coli AdSS (PDB ID: 
2GCQ) with an overall root-mean-square deviation (RMSD) of 1.30 Å across 378 residues. 
Of the 430 residues in the C. neoformans sequence, only 388 could be modelled in each 
chain, as regions corresponding to residues 51-58, 122-141, 171-194 were disordered. 
These missing residues corresponded to the flexible active site loops described in other 
species (41), which only become ordered in these species when the enzyme is fully ligated. 
Confirmation of AdSS dimerization 
To confirm the homodimeric AdSS arrangement seen in our crystal structure, we used 
Size exclusion chromatography linked to multi-angle light scattering (SEC-MALS) to 
determine the molecular weight of our purified AdSS in solution. The monomeric molecular 
weight of the recombinant AdSS protein is ~48 kDa, while the measured molecular weight 
analyzed by SEC-MALS is ~97 kDa (Fig 12B), consistent with the protein forming a stable 
dimer. AdSS dimerization is stabilized by the binding of IMP, and our SEC-MALS analysis 
was performed without ligands. However, AdSS dimerization in physiological 
concentrations is governed by an equilibrium between monomer and dimer, an equilibrium 
that substrate binding tips towards the dimer. Because the standard enzyme 
concentrations used in our SAX-MALs experiments were approximately ten times above 
the dimer’s dissociation constant in other species (46), the dimerization of the C. 
neoformans apoenzyme is most likely the result of this elevated concentration allowing the 
enzyme to dimerise without substrates. 
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Fig 12. Crystal structure of apo-AdSS. (A) Crystal structure of C. neoformans AdSS dimer 
(shown in cartoon form). Gold and red indicate separate monomers. (B) SEC-MALS 
analysis of AdSS. The blue line indicates the trace from the refractive index detector 
(arbitrary units) during SEC. The red line indicates the molecular weight (Y- axis) 
determined by MALS, distributed across the SEC peak. 
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Chapter 6: Ligated AdSS enzyme 
Crystal structure of ligated cryptococcal AdSS 
In order to obtain a more complete C. neoformans AdSS model and better facilitate 
accurate comparison of the fungal enzyme to structures from other species, we set up co-
crystallization experiments whereby IMP, GTP, magnesium acetate and the aspartate 
analogue hadacidin were all included. The corresponding structure was determined to a 
resolution of 1.55 Å (Fig 13), a significant improvement in resolution and general B-factors 
(reflecting the mobility of the atoms, with higher numbers corresponding to higher mobility) 
over the structure of the apoenzyme (Fig 14). The ligated structure was a homodimer, with 
429 of the 430 expected residues in chain A and 413 of 430 residues in chain B. IMP is 
clearly resolved in the active site of each subunit, with B-factors  ranging from 13 to 41 Å2 
in chain A, and 12 to 38 Å2 in chain B. Instead of GTP, the hydrolyzed form GDP is found 
in both active sites, with B-factors ranging from 15 to 21 Å2 in Chain A, and 14 to 38 Å2 in 
Chain B (Fig 15). Hadacidin was not apparent in its expected binding location despite 
being present in 10-fold molar excess during crystallization. Along with the apo-AdSS 
structure produced initially, this represents the first example of an AdSS crystal structure 
solved from a fungal species. 
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Fig 13. Crystal structure of IMP- and GDP-bound AdSS. (A) Crystal structure of C. 
neoformans AdSS dimer (shown in cartoon form) bound to IMP and GDP. Orange and 
magenta indicate separate monomers. Bound ligands IMP and GDP are shown in stick 
form, colored green.(B) Surface mesh of AdSS dimer rotated clockwise in 90º increments 
to display the active-site clefts. IMP and GDP are shown in stick form, colored green 
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Fig 14, B-factor putty diagram comparison of apo- and ligand-bound structures of C. 
neoformans AdSS. Warmer colours and wider tubes indicate higher B-factors, while cooler 
colours and narrow tubes indicate lower B-factors. Images are viewed at the same 
orientation, highlighting improvement in B-factors in the ligand-bound structure. 
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Fig 15, IMP and GDP are clearly resolved in the ligated AdSS structure. (A) Fourier map 
overlay of ligands, indicating electron density at each ligand location. Contour of maps is 
2.0 sigma, radius 1.6 Å. (B) Hydrogen bonds between ligands and indicated protein side-
chains. All images created using Chain A of the AdSS homodimer. 
As with the structure of the apo-enzyme, the fold of the ligated enzyme resembles that 
seen in other AdSS proteins. A central core comprised of a twisted nine-strand β-sheet is 
surrounded by three domains, all combining to form a cleft in which the predicted active 
site is located (Fig 8B). The most dramatic divergence from the common fold is the β-sheet 
referred to as B2 in E. coli. This sheet is longer in chain A of the ligated Cryptococcus 
structure, corresponding to a 5-residue insertion at the tip of the β-sheet that is not 
conserved in any other species (Fig 16). This extended β-sheet is on the opposite side of 
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the structure from the dimerization surface, but is adjacent to the GTP-binding site. In 
chain B, the entire B2 sheet is unresolved.  
 
Fig 16. C. neoformans AdSS contains an extended B2 β-sheet. (A) Comparison of the B2 
β-sheet from E. coli (green, left), C. neoformans (orange, center) and H. sapiens (blue, 
right) AdSS. The structures are shown in cartoon representation. The PDB IDs for the E. 
coli, C. neoformans and human structures are 2GCQ, 5I34 and 2V40 respectively. (B) 
Alignment of B2 β-sheet sequence from multiple species, with general conservation of 
residues annotated in black, GTP-binding residues annotated in green and magnesium-
binding residues annotated in purple. The C. neoformans enzyme contains a 5-residue 
extension found in no other species examined. 
Comparison of C. neoformans and human AdSS active sites 
In order to detect exploitable species-specific structural features in the fungal AdSS 
structure, we compared the active site region of our crystal structure with that from the 
human AdSS structure (PDB ID 2V40). This structure has been deposited in the PDB 
archive, but has not yet been described in a dedicated publication. It was crystallized in 
combination with GDP, which is well resolved in its active site with B-factors of individual 
atoms ranging from 18 to 27 Å2. 
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Pairwise structural alignment of the ligand-bound C. neoformans and human AdSS 
structures returns a close match, with an RMSD of 1.16 Å across 408 residues. The 
human structure contains one gap in visible residue coverage, stretching between 
residues 150-163. This gap corresponds to the active site loop associated with IMP, 
consistent with the previously reported requirement of IMP binding for a fully ordered 
active site and the lack of bound IMP in this structure. The lack of density for this loop 
means that the IMP-binding site is incomplete, rendering a complete comparison of this 
site between the human and C. neoformans AdSS enzymes impossible.  
Partial comparisons can be made, however. In the C. neoformans AdSS, the loop located 
between residues 305-308 is turned towards IMP, presenting the IMP-binding residue 
R308 to the ligand. In the human structure, this loop is turned away from the empty IMP-
binding site. This loop is also associated with the binding of l-aspartate and hadacidin, and 
is conserved between the two enzyme sequences. These structural changes are most 
likely to be the result of the presence of IMP in the cryptococal enzyme. 
Both human and C. neoformans structures feature a complete and occupied GTP/GDP-
binding site, allowing for a more comprehensive comparison. The areas adjacent to the 
GTP-binding site show significant structural changes, primarily the differing position of the 
aforementioned IMP/hadacidin/aspartate-binding loop, as well as the C. neoformans-
specific B2 sheet extension. These differences result in an active site cleft that is more 
“open” above the bound GDP molecule in the C. neoformans structure (Fig 17A).  
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Fig 17. Comparing the GDP binding site of fungal and human AdSS. (A) Comparison of 
the GTP-binding pockets from C. neoformans (orange, left) and H. sapiens (blue, right) 
AdSS. The structures are shown in surface representation. In H. sapiens AdSS, lysine 447 
(B-factors: 23-32 Å2) projects across the active site, in contrast to proline 421 (B-factors: 
68-72 Å2) in the equivalent position in C. neoformans AdSS. Also annotated are the B2 β-
sheet, which is extended in C. neoformans, and the adjacent l-aspartate-binding loop. The 
PDB ID for the H. sapiens structure is 2V40. (B) Alignment of the C-terminal end of AdSS 
sequence from multiple species, with general conservation of residues annotated in black 
and variant lysine/proline residue annotated in green. Fungal and bacterial enzymes 
contain a proline at the marked position, while mammalian enzymes contain a lysine. 
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The GDP-binding pocket itself is less variable between the two enzymes, but has one 
significant change. In humans, the side-chain of residue K447 projects across the GTP-
binding crevice, close to the nucleobase end of the bound GDP. In Cryptococcus, this 
residue is replaced with a proline (P421) (Fig 17A). Interestingly, the alignment of AdSS 
sequences across several organisms shows that the C. albicans, A. fumigatus, 
Arabidopsis thaliana and E. coli enzymes also have a proline at this position. In 
comparison, both isoforms from humans and mice have a lysine at this position (Fig 17B). 
Finally, the human enzyme also features a long segment at its N-terminus that does not 
appear in the sequence of the enzyme from C. neoformans, nor any of the lower 
eukaryotes or bacteria (Fig S1). This feature is present in both isoforms from both humans 
and mice, is 26 residues long in isoform 1 and 22 residues long in isoform 2, and is well 
conserved between species and isoforms. This region has not been modelled in the crystal 
structures from either mouse or human enzymes, suggesting it is flexible. 
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Chapter 7 – Discussion 
With the increasing burden placed on our healthcare system by opportunistic fungal 
pathogens and the rise of antifungal resistance, new drug targets and novel antifungal 
compounds are urgently needed. Here, we have characterized the ubiquitous purine 
biosynthetic enzyme adenylosuccinate synthetase from the fungal pathogen Cryptococcus 
neoformans. In the process, we have revealed its potential as a target for the treatment of 
cryptococcal disease.  
That the C. neoformans ade12∆ mutant displayed a loss of virulence, while the aph1∆ 
adenine salvage-deficient strain did not, is consistent with other studies into the 
importance of de novo purine metabolism in pathogenesis. Purine biosynthesis mutants of 
many bacterial pathogens, such as Listeria monocytogenes (103), Yersinia pestis (104), 
Bacillus anthracis (105) and Staphylococcus aureus (106), are avirulent. C. albicans, another 
opportunistic fungal pathogen, is also rendered avirulent by disruption of de novo purine 
biosynthesis (107). 
The effects of disruption of purine salvage on microbial pathogens are not as well known. 
It has been known for over 40 years that obligate protozoan parasites are unable to 
synthesize purines de novo (108) and lack any of the required purine de novo biosynthetic 
genes (109). Fittingly, purine salvage has been found to be essential in several obligate 
intracellular protozoan pathogens, including Toxoplasma gondii (109), Plasmodium 
falciparum (110) and Leishmania donovani (111), as well as the bacterial pathogen 
Helicobacter pylori (112). While this would seem to run contrary to the ubiquity of the 
pathway in other organisms, the intracellular location of these parasites means that they 
can exploit their host’s purine production, a luxury C. neoformans cannot enjoy due to its 
purine-poor niche in the central nervous system (32). Indeed, our findings confirm that 
purine salvage via Aph1 is not necessary or sufficient for C. neoformans during infection.  
The dependence of C. neoformans on de novo purine biosynthesis during infection is in 
line with the model for Cryptococcus virulence suggested by our previous work with GTP 
biosynthetic enzymes (31). In this model, purine salvage enzymes such as Aph1 and Hpt1 
are dispensable for infection due to insufficient concentrations of environmental purines in 
the human central nervous system. During infection, C. neoformans must rely almost 
exclusively on de novo purine synthesis. Disruption of this pathway renders it avirulent 
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irrespective of virulence factor production, highlighting the potential of AdSS as an 
anticryptococcal drug target.  
Hadacidin is an AdSS inhibitor that has been known to have antitumour activity since the 
early 1960s (56). Despite being partially active against C. neoformans AdSS in vitro, 
hadacidin displayed no antifungal activity against C. neoformans cells, and only a limited 
degree of activity against C. albicans. This was possibly due to the concentrations of 
hadacidin tested in vivo being too low to engender an antifungal effect. However, even if 
hadacidin had been present in sufficient quantities to effect fungal growth, our in vitro 
assays suggests that it may not be able to fully inhibit the activity of C. neoformans AdSS 
on its own. The plateau in the inhibitory activity of hadacidin observed at high 
concentrations during our IC50 experiments indicates that not even therapeutically 
problematic millimolar concentrations of the drug would completely inhibit the enzyme. 
This is at odds with previous in vitro work completed using purified AdSS from 
Dictyostelium discoideum (113) and E. coli (61), which showed that 100% inhibition was 
possible at similar compound concentrations. E. coli enzyme studies performed by 
Tibrewal and Elliot (61) showed that the inhibitory activity of hadacidin decreased to 80% 
when the ratio of aspartate to hadacidin was increased from 1:1 to 5:1, suggesting a 
competitive inhibition of AdSS by hadacidin. Our assays using the Crytococcus AdSS were 
performed at a ratio higher than this, at least 10:1, due to the high concentration of 
aspartate required to saturate the C. neoformans enzyme. Indeed, the significantly higher 
KM for aspartate exhibited by C. neoformans AdSS compared to E. coli indicates a 
difference in the two enzymes' affinity for aspartate, and therefore hadacidin or any other 
potential inhibitors targeting this binding pocket. This may explain the inability of hadacidin 
to completely inhibit the cryptococcal enzyme, and suggests that a full kinetic analysis of 
hadacidin and aspartate binding to AdSS would be useful. Since this would require us to 
synthesize large amounts of the inhibitor which is not currently commercially available, it is 
outside the scope of the current study. 
AdSS has been crystallized in a variety of ligand-bound forms, with hadacidin acting as a 
common stand-in for l-aspartate during attempts to crystallize a fully ligated enzyme. 
Previous studies with the E. coli and mouse enzymes have reported that, when crystallized 
with IMP and GTP, AdSS was resolved as a stable complex with GDP and the 
intermediate 6-PIMP regardless of the inclusion or absence of hadacidin (98, 114). This 
corresponds to a “frozen” intermediate state in the AdSS reaction, in which the γ-
phosphate of GTP is transferred to the 6-oxygen position of IMP. The reaction is unable to 
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continue to completion without l-aspartate. In our structure, there is no visible electron 
density supporting the presence of a phosphate group at the γ position of GDP, indicating 
that the initial hydrolysis of GTP has taken place in the crystallized complex. However, no 
corresponding phosphate was detected at the 6-oxygen position of IMP. This may indicate 
that the AdSS-IMP-GTP/GDP complex was captured here in a state of flux between the 
two binding states, that GTP was hydrolyzed to GDP before crystal formation began and 
bound to the GTP binding pocket regardless (a complex seen in other GDP-bound AdSS 
structures, including the human structure used in this study), or that it was hydrolyzed in 
the time it took for crystals to form.  
Despite this, we were still able to use our ligated crystal structure to directly compare the 
GDP-binding sites of C. neoformans and human AdSS in their bound contexts, a 
significant step forward in the process of designing species-specific AdSS inhibitors. The 
GDP-binding site is well resolved in C. neoformans and human AdSS structures and 
exhibits one of the most significant observable difference between the two enzymes – the 
replacement of a lysine side-chain in the human enzyme with a proline in the C. 
neoformans enzyme. These amino acids have markedly different properties; lysine side-
chains are flexible and are often involved in hydrogen bonding, and carry a positive 
charge, while proline side-chains are rigid and uncharged. In the human structure, this 
lysine projects across the GTP-binding site, while the much shorter proline does not.  
This divergence in the GTP-binding site may help explain the differences in GTP KM 
values between the cryptococcal and mammalian enzymes (Table 1), although further 
investigation into both the human and C. neoformans crystal structures and kinetic 
mechanisms would be required to confirm this. Additionally, the fact that that the bacterial, 
fungal and plant orthologs of AdSS share a proline at this residue, while human and 
mouse sequences share a lysine, suggest that this lysine may be a mammalian-specific 
feature. If this is true, it may be possible to use this change in residues to design inhibitors 
with a broad spectrum of antimicrobial activity that still maintain the specificity needed to 
avoid harming mammalian patients. 
The second significant difference between the human and C. neoformans structure is the 
Cryptococcus-specific extension to the B2 β-sheet. While this feature is located adjacent to 
the GDP-binding site, and was only fully resolved in the ligand-bound protein structure, it 
does not appear to be directly involved in substrate binding. The function, if any, of this 
extended sheet could be further determined via targeted deletion mutation experiments. 
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The mismatched resolution of this segment between the two chains of our crystal structure 
is most likely related to the packing of molecules in our crystals.  
In summary, here I have demonstrated that ATP biosynthesis is crucial for C. neoformans 
virulence, but not for virulence factor production. In contrast, adenine salvage is neither 
necessary nor sufficient for cryptococcal virulence. I have characterised the kinetic 
parameters of the purine biosynthetic enzyme AdSS, and tested the efficacy of an existing 
AdSS inhibitor on the fungal enzyme, as well as living cells. I have also presented the first 
crystal structure of an AdSS enzyme from a fungal species, and described the species-
specific differences in the otherwise-conserved AdSS that mark it as a strong candidate for 
further development of inhibitors. In particular, the discovery of a proline residue in the 
enzyme’s GTP-binding pocket that is conserved in fungal, bacterial and plant species, but 
not in mammals, paves the way for the potential development of agents with a broad-
spectrum of antimicrobial and herbicidal activity. 
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Appendices 
 
Table S1: Primers used in this project 
 
Name Purpose Sequence 
   
UQ1742 ADE12 5’ flank 
overlap forward 
AGCTTGAAATAACACACACGC 
UQ1743 ADE12 5’ flank 
overlap reverse 
TCCAGCTCACATCCTCGCAGCCTAGAATAGATAGG 
UQ1744 ADE12 3’ flank 
overlap forward 
CCGTGTTAATACAGATAAACCGAAGATCGAAAGTT 
UQ1745 ADE12 3’ flank 
overlap reverse 
TTTCATTACGTACCCAGAACC 
UQ1830 ADE12 NEO 
overlap forward 
CCTATCTATTCTAGGCTGCGAGGATGTGAGCTGGAG 
 
UQ1831 ADE12 NEO 
overlap reverse 
AAACTTTCGATCTTCGGTTTATCTGTATTAACACGG 
 
UQ1750 APH1 5’ flank 
overlap forward 
AGATGACTAACCGGGAGGTAA 
 
UQ1751 APH1 5’ flank 
overlap reverse 
CAGCTCACATCCTCGCAGCGGTGGAAAGGGTGTGT 
 
UQ1752 APH1 3’ flank 
overlap forward 
GTTAATACAGATAAACCAGGTCAAGGGTATTTTAG 
 
UQ1753 APH1 3’ flank 
overlap reverse 
AAGTGTCCTGTCCAAGCCAGA 
 
UQ1834 APH1 NEO 
overlap forward 
ACACACCCTTTCCACCGCTGCGAGGATGTGAGCTGG 
 
UQ1835 APH1 NEO 
overlap reverse 
ACTAAAATACCCTTGACCTGGTTTATCTGTATTAAC 
 
UQ2051 ADE12 TOPO 
sequencing 
primer 1 
GGCATTTATTAATCATTCTCA 
UQ2052 ADE12 TOPO 
sequencing 
primer 2 
ACGTCCCTTCGCTTTTCAATG 
UQ2053 ADE12 TOPO 
sequencing 
primer 3 
GTGTCGTCGGTGTCATCAAGG 
UQ2054 ADE12 TOPO 
sequencing 
primer 4 
AAGGTTCAATACGTCGGTGTT 
UQ2055 ADE12 TOPO 
sequencing 
primer 5 
TGTTGTGTTGTGTTCGCTGTG 
UQ2063 APH1 TOPO 
sequencing 
primer 1 
TTACGGGCTTCACGCTTTTCG 
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UQ2064 APH1 TOPO 
sequencing 
primer 2 
ACACACAGGGCATCACCTTCC 
UQ2065 APH1 TOPO 
sequencing 
primer 3 
CCCGTTTACTCCATGATTGAG 
UQ2066 APH1 TOPO 
sequencing 
primer 4 
GGGGGCTGAAAACCATAGTAT 
UQ2259   ADE12 
expression 
upper 
ACGCACGGATCCATGGCTCCATCCCCGGAGGGA 
UQ2260 ADE12 
expression 
lower 
GAACGTCTGCAGTTAGAAGATGATAACGTTCTG 
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Table S2: Fungal strains used in this project. 
 
Strain  Species Strain Details Source 
    
H99 Cryptococcus neoformans 
var. grubii 
Laboratory type-
strain 
John 
Perfect 
SDMA17 Cryptococcus neoformans 
var. grubii 
ade12::NEO This 
study 
RBD01 Cryptococcus neoformans 
var. grubii 
ade12::NEO 
ADE12-NAT 
This 
study 
AK3 Cryptococcus neoformans 
var. grubii 
aph1::NEO This 
study 
KLB02 Cryptococcus neoformans 
var. grubii 
aph1::NEO APH1-
NAT 
This 
study 
ATCC 
90113 
Cryptococcus neoformans 
var. grubii 
ATCC reference 
strain 
ATCC 
ATCC 
90028 
Candida albicans ATCC reference 
strain 
ATCC 
ATCC 
90030 
Candida galbrata ATCC reference 
strain 
ATCC 
ATCC 
22019 
Candida parapsilosis ATCC reference 
strain 
ATCC 
ATCC 
MYA-3626 
Aspergillus fumigatus ATCC reference 
strain 
ATCC 
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Table S3: Crystallographic statistics for C. neoformans AdSS structures. Statistics 
for the highest-resolution shell are shown in parentheses. All statistics generated by 
Phenix. 
 
Diffraction data statistics Apo AdSS Ligated AdSS 
Space group P 21 21 21 P 21 21 21 
Unit cell parameters  
a, b, c (Å); α=β=γ (°) 
58.08, 101.00, 
163.80;  
90 
55.81, 100.77, 
163.80; 90 
Molecules per asymmetric 
unit 
2 2 
Resolution range (Å) 37.02 - 2.20 (2.28 - 
2.20) 
46.12 - 1.53 (1.58 - 
1.53) 
No. unique observations 49,839 140,564 
Completeness (%) 99.8 (99.9) 99.9 (99.4) 
Multiplicity  7.1 (7.3) 7.3 (7.1) 
Average I/σ(I) (%) 19.8 (2.1) 16.6 (2.77) 
R-merge (%)a 0.066 (1.25) 0.077 (0.68) 
R-measb 0.072 0.083 
CC1/2 0.999 (0.879) 0.999 (0.858) 
   
Refinement statistics   
Resolution (Å) 37.02 - 2.20 46.12 - 1.53 
No. of reflections work set 47,774 138,564 
No. of reflections test set 1,998 (4%) 2,000 (1.4%) 
Rworkb  0.209 0.143 
Rfreec  0.246 0.194 
No. protein atoms 2 2 
No. water molecules 85 805 
Overall B-factor (Å2) 61.60 21.70 
RMS deviations from ideal 
values 
  
Bonds (Å) 0.009 0.006 
Angles (º) 1.10 0.98 
Ramachadran plot   
Favoured (%) 97 98 
Disallowed (%) 0.4 0 
 
 
aRmerge = ∑hkl(∑i(|I hkl,I − <I hkl >|))/∑hkl,i <I hkl>, where I hkl,i is the intensity of an individual 
measurement of the reflection with Miller indices h, k, and l, and <Ihkl> is the mean intensity 
of that reflection. Calculated for I > −3σ(I). 
 
bRmeas = ∑hkl{N(hkl)/[N(hkl)-1]}1/2 ∑i|Ii(hkl)- |/ ∑hkl∑iIi(hkl), where Ii(hkl) is the intensity 
of the ith measurement of an equivalent reflection with indices hkl. 
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cRwork = Σhkl(||Fobshkl| − |Fcalchkl||)/|Fobshkl|, where |Fobshkl| and |Fcalchkl| represent the 
observed and calculated structure factor amplitudes.  
dRfree is equivalent to Rwork but calculated using the reflections excluded from refinement in 
the test set. 
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Fig S1: Sequence alignment of AdSS genes from multiple species. Secondary 
structure elements from the E. coli structure annotated above. Colored columns indicate 
residues involved in substrate contacts, with orange indicating IMP-binding residues, 
green indicating GTP, blue indicating aspartate, and purple indicating magnesium. 
 
